A phase 1 dose escalation study of the safety and pharmacokinetics of the KIT inhibitor XL820 administered orally daily to subjects with solid tumors

Trial Profile

A phase 1 dose escalation study of the safety and pharmacokinetics of the KIT inhibitor XL820 administered orally daily to subjects with solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2008

At a glance

  • Drugs XL 820 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 17 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov
    • 12 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top